Eagle Point Income Company (EIC) is rated a Buy due to its attractive 15% yield and historically wide 30% discount to its net asset value (NAV). Despite market fears and a sharp price decline, EIC's NAV has remained stable, with monthly distributions fully covered by net investment income. The fund is shifting its portfolio towards higher-performing credit assets, reducing exposure to CLO equity below 20%, and has redeemed its Series A Term Preferred Shares. Rising interest rates are expected to benefit EIC's floating rate loan portfolio, supporting stable distributions and improving coverage ahead of its Q3 earnings report.
Eagle Point Income Company is the subject of this market context snapshot. For readers following US stocks, here is Pluang's market snapshot as of Nov 11, 2026 01:31 WIB: Out of 150 priced US stocks tradable on Pluang, 48 rose and 102 fell today. Notable movers include LCID at USD 3.89 with a +8.06% change, GFI at USD 37.97 with a -7.48% change, and FCEL at USD 10.09 with a -6.75% change.
As of October 31, 2026, EssilorLuxottica disclosed its total number of shares at 464,247,548 and actual voting rights at 458,376,127 after deducting treasury shares. The company enforces a 31% voting rights cap per shareholder, as outlined in its sta...
EssilorLuxottica disclosed its share capital and voting rights as of October 31, 2026, reporting 464,247,548 shares outstanding and 458,376,127 real voting rights excluding treasury shares. The company applies a 31% cap on voting rights per sharehold...
The global peptide therapeutics market is projected to grow from $112.2 billion in 2026 to $229.32 billion by 2036, at a CAGR of 7.4%. Growth is fueled by expanding use of GLP-1 and incretin therapies, advances in peptide engineering, new oncology ap...
Science 37, a direct-to-patient clinical research site, was named a BioSpace 2027 Best Place to Work, recognized for its innovative culture and commitment to clinical quality. The company’s model brings clinical trials to patients' homes, improving a...
Book Leopard, a new AI software, enables authors and publishers to create professional-quality Amazon book marketing materials in seconds for a one-time fee of $49, drastically reducing costs from over $1,000 and weeks of waiting. The tool generates ...
